GB201903827D0 - New compounds and methods - Google Patents

New compounds and methods

Info

Publication number
GB201903827D0
GB201903827D0 GBGB1903827.2A GB201903827A GB201903827D0 GB 201903827 D0 GB201903827 D0 GB 201903827D0 GB 201903827 A GB201903827 A GB 201903827A GB 201903827 D0 GB201903827 D0 GB 201903827D0
Authority
GB
United Kingdom
Prior art keywords
methods
new compounds
compounds
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1903827.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atrogi AB
Original Assignee
Atrogi AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atrogi AB filed Critical Atrogi AB
Priority to GBGB1903827.2A priority Critical patent/GB201903827D0/en
Publication of GB201903827D0 publication Critical patent/GB201903827D0/en
Priority to EP20728536.2A priority patent/EP3941468A1/en
Priority to MX2021011286A priority patent/MX2021011286A/es
Priority to TW109109482A priority patent/TWI846843B/zh
Priority to KR1020217033753A priority patent/KR20210141622A/ko
Priority to CA3133768A priority patent/CA3133768A1/en
Priority to AU2020243426A priority patent/AU2020243426A1/en
Priority to PCT/GB2020/050762 priority patent/WO2020188301A1/en
Priority to US17/439,668 priority patent/US20220152004A1/en
Priority to BR112021018578A priority patent/BR112021018578A2/pt
Priority to CN202080032751.5A priority patent/CN113784953A/zh
Priority to JP2021556591A priority patent/JP2022525795A/ja
Priority to IL286432A priority patent/IL286432A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1903827.2A 2019-03-20 2019-03-20 New compounds and methods Ceased GB201903827D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB1903827.2A GB201903827D0 (en) 2019-03-20 2019-03-20 New compounds and methods
JP2021556591A JP2022525795A (ja) 2019-03-20 2020-03-20 高血糖症の治療に有用なヘテロシクロリル（フェニル）メタノール化合物
AU2020243426A AU2020243426A1 (en) 2019-03-20 2020-03-20 Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia
MX2021011286A MX2021011286A (es) 2019-03-20 2020-03-20 Compuestos de heterociclil(fenil)metanol útiles en el tratamiento de la hiperglucemia.
TW109109482A TWI846843B (zh) 2019-03-20 2020-03-20 適用於治療高血糖症的雜環基(苯基)甲醇化合物
KR1020217033753A KR20210141622A (ko) 2019-03-20 2020-03-20 과혈당증의 치료에 유용한 헤테로시클릴(페닐)메탄올 화합물
CA3133768A CA3133768A1 (en) 2019-03-20 2020-03-20 Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia
EP20728536.2A EP3941468A1 (en) 2019-03-20 2020-03-20 Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia
PCT/GB2020/050762 WO2020188301A1 (en) 2019-03-20 2020-03-20 Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia
US17/439,668 US20220152004A1 (en) 2019-03-20 2020-03-20 Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia
BR112021018578A BR112021018578A2 (pt) 2019-03-20 2020-03-20 Compostos de heterociclil(fenil)metanol úteis no tratamento de hiperglicemia
CN202080032751.5A CN113784953A (zh) 2019-03-20 2020-03-20 可用于治疗高血糖症的杂环基(苯基)甲醇化合物
IL286432A IL286432A (en) 2019-03-20 2021-09-14 Methanol compounds bearing phenyl and a heterocyclic ring are useful in the treatment of hyperglycemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1903827.2A GB201903827D0 (en) 2019-03-20 2019-03-20 New compounds and methods

Publications (1)

Publication Number Publication Date
GB201903827D0 true GB201903827D0 (en) 2019-05-01

Family

ID=66381053

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1903827.2A Ceased GB201903827D0 (en) 2019-03-20 2019-03-20 New compounds and methods

Country Status (13)

Country Link
US (1) US20220152004A1 (enExample)
EP (1) EP3941468A1 (enExample)
JP (1) JP2022525795A (enExample)
KR (1) KR20210141622A (enExample)
CN (1) CN113784953A (enExample)
AU (1) AU2020243426A1 (enExample)
BR (1) BR112021018578A2 (enExample)
CA (1) CA3133768A1 (enExample)
GB (1) GB201903827D0 (enExample)
IL (1) IL286432A (enExample)
MX (1) MX2021011286A (enExample)
TW (1) TWI846843B (enExample)
WO (1) WO2020188301A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
GB202204085D0 (en) * 2022-03-23 2022-05-04 Atrogi Ab New compounds and methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985887A (en) * 1973-10-19 1976-10-12 Smithkline Corporation 3-Substituted-4-hydroxyphenyl-2-piperidylcarbinols as β-adrenergic stimulants
US3910933A (en) * 1973-10-19 1975-10-07 Smithkline Corp 3-Substituted-4-hydroxyphenyl-2-piperidylcarbinols
NO753594L (enExample) * 1974-10-30 1976-05-03 Scherico Ltd
FR2436779A1 (fr) * 1978-09-22 1980-04-18 Pharmindustrie Derives de pyrrolidine-2 methanol utilisables comme medicaments
FR2460929A1 (fr) * 1979-07-06 1981-01-30 Roussel Uclaf Nouveaux derives de l'a-phenyl 2-pyrrolidinemethanol et leur sels, procede de preparation, application a titre de medicaments et compositions les renfermant
EP0128120A3 (de) * 1983-06-02 1985-11-13 Ciba-Geigy Ag Trisubstituierte Oxazolidinone
PT1087662E (pt) * 1998-06-18 2002-09-30 Novartis Ag Composicao para manter afastada a vermina
AR019867A1 (es) * 1998-06-18 2002-03-20 Novartis Ag Uso de un derivado de pirrolidina para la fabricacion de un repelente contra insectos, acaros y garrapatas, dicho compuesto, una composicion que locomprende, un proceso para la preparacion de dicha composicion, y un proceso para repeler insectos de lugares y materiales
GB0419828D0 (en) * 2004-09-07 2004-10-13 Arakis Ltd The treatment of inflammatroy disorders and pain
WO2006027579A2 (en) * 2004-09-07 2006-03-16 Sosei R & D Ltd. The treatment of inflammatory disorders and pain
GB2435979A (en) * 2006-03-07 2007-09-12 Helen Theresa Haywood Door intercom telephone device
FR2917735B1 (fr) * 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
GB201714740D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses

Also Published As

Publication number Publication date
US20220152004A1 (en) 2022-05-19
KR20210141622A (ko) 2021-11-23
EP3941468A1 (en) 2022-01-26
CA3133768A1 (en) 2020-09-24
MX2021011286A (es) 2022-01-24
IL286432A (en) 2021-10-31
TW202102473A (zh) 2021-01-16
TWI846843B (zh) 2024-07-01
JP2022525795A (ja) 2022-05-19
CN113784953A (zh) 2021-12-10
AU2020243426A1 (en) 2021-11-04
WO2020188301A1 (en) 2020-09-24
BR112021018578A2 (pt) 2021-11-23

Similar Documents

Publication Publication Date Title
ZA202001447B (en) M-diamide compound and preparation method therefor and use thereof
ZA202105643B (en) Processes and compounds
IL285177A (en) compounds and their use
IL286497A (en) compounds and their use
GB201903827D0 (en) New compounds and methods
GB201907882D0 (en) Methods
IL291499A (en) Azaquinoline compounds and their uses
ZA202105752B (en) Haloallylamine compounds and application thereof
GB201903832D0 (en) New compounds and methods
SG11202108079RA (en) Compounds and uses thereof
GB201801102D0 (en) New compounds and uses
IL284764A (en) compounds and their uses
GB202015044D0 (en) New compounds and methods
GB202015035D0 (en) New compounds and methods
GB201906705D0 (en) Methods
GB201911127D0 (en) Materials and methods
GB201913716D0 (en) Methods
GB202113594D0 (en) New compounds and methods
GB201913110D0 (en) New compounds and methods
GB201903909D0 (en) Methods
GB201911130D0 (en) MAterials and methods
ZA202201239B (en) Aminothiolester compounds and uses thereof
GB202113588D0 (en) New compounds and methods
GB201908348D0 (en) Methods
GB201907157D0 (en) Methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)